References

1. Gershenson DM: Clinical management of potential tumors of low malignancy. Best Pract Res Clin Obstet Gynaecol 16:513527, 2002.

2. Skirnisdottir I, Garmo H, Wilander E, et al: Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis. Int J Cancer 15:123(8):1897-1901, 2008.

3. Lu KH, Bell DA: Borderline ovarian tumors. In Gershenson DM, McGuire WP, Gore M, et al (eds): Gynecologic Cancer: Controversies in Management. Philadelphia: Elsevier, 2004, pp 519-526.

4. Harlow BL, Weiss NS, Lofton S: Epidemiology of borderline ovarian tumors. J Natl Cancer Inst 78:71-74, 1987.

5. Silverberg SG, Bell DA, Kurman RJ, et al: Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35:910-917, 2004.

6. Jones MB: Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 49:517-525, 2006.

7. Gershenson DM: Is micropapillary serous carcinoma for real? Cancer 95:677-680, 2002.

8. Bell DA, Weinstock MA, Scully RE: Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis. Cancer 62:2212-2222, 1988.

9. Russell P: Borderline epithelial tumours of the ovary: a conceptual dilemma. Clin Obstet Gynecol 11:259-277, 1984.

10. Michael H, Roth LM: Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 57:1240-1247, 1986.

11. Gershenson DM, Silva EG, Tortolero-Luna G, et al: Ovarian serous borderline tumors with noninvasive peritoneal implants. Cancer 83:2157-2163, 1998.

12. Gershenson DM, Silva EG, Levy L, et al: Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 82:1096-1103, 1998.

13. Buttin BM, Herzog TJ, Powell MA, et al: Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 99:11-17, 2002.

14. Hogg R, Scurry J, Kim SN, et al: Microinvasion links serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol 106:44-51, 2007.

15. Crispens MA, Bodurka D, Deavers M, et al: Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3-10, 2002.

16. Longacre TA, McKenney JK, Tazelaar HD, et al: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (= 5 years) follow-up. Am J Surg Pathol 29:707-723, 2005.

17. Ren J, Peng Z, Yang B: A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol Oncol 110:162-167, 2008.

18. Seidman JD, Kurman RJ: Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors). Cancer 95:675-676, 2002.

19. Bristow RE, Gossett DR, Shook DR, et al: Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 86:163-170, 2002.

20. Eichhorn JH, Bell DA, Young RH, et al: Ovarian serous borderline tumors with micropapillary and cribiform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 23:397-409, 1999.

21. Boran N, Cil AP, Tulunay G, et al: Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 97:845-851, 2005.

22. But I: Serum Ca-125 level as a reflection of proliferative activity of serous borderline ovarian tumor. Int J Gynecol Obstet 71:289-291, 2000.

23. Gotleib WH, Soriano D, Achiron R, et al: Ca-125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol 183:541-546, 2000.

24. Rice LW, Lage JM, Berkowitz RS, et al: Preoperative Ca-125 levels in borderline tumors of the ovary. Gynecol Oncol 46(2):226-229, 1992.

25. Engelen MJA, de Bruijn HWA, Hollema H, et al: Serum CA-125, cardinoembryonic antigen, and CA19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 78:16-20, 2000.

26. Tamakoshi K, Kikkawa F, Shibata K, et al: Clinical value of Ca-125, Ca-19-9, CEA, CaA 72-4 and TPA in borderline ovarian tumor. Gynecol Oncol 62:67-72, 1996.

27. Geomini P, Bremer G, Kruitwagen R, et al: Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 96:1-9, 2005.

28. Tempfer CB, Polterauer S. Bentz EK, et al: Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 107:248-252, 2007.

29. Morris RT, Gershenson DM, Silva EG, et al: Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 95:541-547, 2000.

30. Suh-Burgmann E: Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population based study. Gynecol Oncol 103:841-847, 2006.

31. Boran N, Cil AP, Tulunay G, et al: Fertility and recurrence rates of conservative surgery for borderline ovarian tumors. Gynecol Oncol 97:845-851, 2005.

32. Poncelet C, Fauvet R, Boccara J, et al: Recurrence after cystec-tomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol 13:565-571, 2006.

33. Winter WE, III, Kucera PR, Rodgers W, et al: Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 100:671-676, 2002.

34. Fauvet R, Boccara J, Dufournet C, et al: Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 100:1145, 2004.

35. Barnhill DR, Kurman RJ, Brady MD, et al: Preliminary analysis of the behavior of stage I ovarian tumors of low malignant potential: a Gynecologic Oncology Group Study. J Clin Oncol 13:2752-2756, 1995.

36. Barakat RR, Benjamin I, Lewis JL, Jr, et al: Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 59:390-393, 1995.

37. Sutton GP, Bundy BN, Omura GA, et al: Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group Study). Gynecol Oncol 41:230-233, 1991.

38. Bristow RE, Gossett DR, Shook DR, et al: Recurrent micropap-illary serous ovarian carcinoma: the role of secondary cytoreduc-tive surgery. Cancer 95:791-800, 2002.

39. Scully R, Sobin, L: Histological Typing of Ovarian Tumours, vol. 9. New York: Springer Berlin, 1999. Copyright 1999 World Health Organization.

40. Evans AT, III, Gaffey TA, Malkasian GD, Jr, et al: Clinicopatho-logic review of 118 granulosa cell and 82 theca cell tumors. Obstet Gynecol 55:231, 1980.

41. Schumer ST, Cannistra SA: Granulosa cell tumor of the ovary. J Clin Oncol 21:1180-1189, 2003.

42. Young RH, Dickerson GR, Scully RE: Juvenile granulosa cell tumor of the ovary: a clinicopathologic analysis of 125 cases. Am J Surg Pathol 8:575-596, 1984.

43. Rodgers RJ, Irving-Rodgers HF, van Wezel IL, et al: Dynamics of the membrane granulosa during expansion of the ovarian fol-licular antrum. Mol Cell Endocrinol 172:41^8, 2001.

44. Fox H, Agrawal K, Langley FA: A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 35:231-241, 1975.

45. Stenwig JT, Hazekamp JT, Beecham JB: Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol 7:136-152, 1979.

46. McCluggage WG: Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 53:327-334, 2000.

47. Gershenson DM: Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 55: S62, 1994.

48. Zhang M, Cheung MK, Shin JY, et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—an analysis of 376 women. Gynecol Oncol 104:396-400, 2007.

49. Gusberg SB, Kardon P: Proliferative endometrial response to theca-granulosa cell tumors. Am J Obstet Gynecol 111:633643, 1971.

50. Miller BE, Barron BA, Wan JY, et al: Prognostic factors in adult granulosa cell tumor of the ovary. Cancer 79:1951-1955, 1997.

51. Bjorkholm E, Silfversward C: Prognostic factors in granulosa-cell tumors. Gynecol Oncol 11:261-274, 1981.

52. Malmstrom H, Hogberg T, Risberg B, et al: Granulosa cell tumor of the ovary: prognostic factors and outcome. Gynecol Oncol 52:50-55, 1994.

53. Schneider DT, Calaminus G, Wessalowski R, et al: Ovarian sex cord stromal tumors in children and adolescents. J Clin Oncol 21:2357-2363, 2003.

54. Al-Badawi IA, Brashner PM, Ghatage P, et al: Postoperative chemotherapy in advanced ovarian granulosa cell tumors. Int J Gynecol Cancer 12:119-123, 2002.

55. Chan JK, Zhang M, Khaleb V, et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-a multivariate analysis. Gynecol Oncol 96:204-209, 2005.

56. Zanagnolo V, Pasinetti B, Sartori E: Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 25:431—438, 2004.

57. Calaminus G, Wessalowski R, Harms D, et al: Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecol Oncol 65:447^52, 1997.

58. Lapphon RE, Burger HG, Bouma J, et al: Inhibin as a marker for granulosa-cell tumors. N Engl J Med 321:790—793, 1989.

59. Jobling T, Mamers P, Healy DL, et al: A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 55:285—289, 1984.

60. Boggess JF, Soules MR, Goff BA, et al: Serum inhibin and disease status in women with ovarian granulosa cell tumors. Gynecol Oncol 64:64—69, 1997.

61. Mom CH, Engelen MJ, Willemse PH, et al: Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 105:365— 372, 2007.

62. Rey RA, Lhomme C, Marcillac I, et al: Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha inhibin and estradiol. Am J Obstet Gynecol 174:958—965, 1996.

63. Lane AH, Lee MM, Fuller AF, et al: Diagnostic utility of mul-lerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 73:51—55, 1999.

64. Hines JF, Khalifa MA, Moore JL, et al: Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 60:484—488, 1996.

65. Homesley HD, Bundy BN, Hurteau JL, et al: Bleomycin, etoposide, and cisplatin combination therapy of granulosa cell tumors and other stromal cell malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 72:131—137, 1999.

66. Gershenson DM, Morris M, Burke TW, et al: Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 87:527—531, 1996.

67. Brown J, Shvartsman HS, Deavers MT, et al: The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22:3517—3523, 2004.

68. Brown J, Shvartsman HS, Deavers MT, et al: The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 97:489—496, 2005.

69. Chiara S, Merlini L, Campora E, et al: Cisplatinum-based chemotherapy in recurrent or high-risk ovarian granulosa cell tumor patients. Europ J Gynaecol Oncol 14:314—317, 1993.

70. Zambetti M, Escobedo A, Pilotti S, et al: Cisplatinum/vinblas-tine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol 36:317—320, 1990.

71. Gershenson DM, Copeland LJ, Kavanaugh JJ, et al: Treatment of metastatic stromal tumors of the ovary with cisplatin, doxo-rubicin, and cyclophosphamide. Obstet Gynecol 70:765—769, 1987.

72. Muntz HG, Goff BA, Fuller AF: Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with a report of a long-term response to a cyclophosphamide, doxorubicin, and cisplatin regimen. Eur J Gynaecol Oncol 11:263—268, 1990.

73. Disaia P, Saltz A, Kagan AR, et al: A temporary response of recurrent granulosa cell tumor to adriamycin. Obstet Gynecol 52:355—358, 1978.

74. Powell JL, Otis CN: Management of advanced juvenile granulosa cell tumor of the ovary. Gynecol Oncol 64:282—284, 1997.

75. Hardy R, Bell J, Nicely C, et al: Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 96:865—869, 2005.

76. Fishman AP, Kudelka, Tresukosol D, et al: Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 41:393-396, 1996.

77. Freeman S, Modesitt S: Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol 103:755-758, 2006.

78. Wolf JK, Mullen J, Eifel PJ, et al: Radiation treatment of advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol 73:35-41, 1999.

79. Savage P, Constenla D, Fisher C, et al: Granulosa cell tumors of the ovary: demographics, survival, and management of advanced disease. J Clin Oncol 10:242-245, 1998.

80. Ishiko O, Yoshida H, Sumi T, et al: Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs syndrome. Eur J Obstet Gynecol Reprod Biol 98:129-130, 2001.

81. Britt KL, Findlay JK: Regulation of the phenotype of ovarian somatic cells by estrogen. Mol Cell Endocrinol 202:11-17, 2003.

82. Young RH, Scully RE: Ovarian Sertoli-Leydig cell tumors: a clinicopathologic analysis of 207 cases. Am J Surg Pathol 9:543569, 1985.

83. Latthe P, Shafi MI, Rollason TP: Recurrence of Sertoli-Leydig cell tumor in contralateral ovary. Case report and review of the literature. Eur J Gynaecol Oncol 21:62-63, 2000.

84. Young RH: Sex cord stromal tumors of the ovaries and testis: their similarities and differences with consideration of selected problems. Mod Pathol 18:S81, 2005.

85. Young RH, Welch RH, Dickerson GR, et al: Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum. Cancer 50:1384-1402, 1982.

86. Puls LE, Hamous J, Morrow MS, et al: Recurrent ovarian sex cord tumor with annular tubules: tumor marker and chemotherapy experience. Gynecol Oncol 54:396^01, 1994.

87. Hart WR, Kumar N, Crissman JD: Ovarian neoplasms resembling sex cord tumors with annular tubules. Cancer 45:23522563, 1980.

88. Ahn GH, Chi JG, Lee SK: Ovarian sex cord tumor with annular tubules. Cancer 57:1066-1073, 1986.

89. Chikvula M, Hunt J, Carter G, et al: Recurrent gynandroblas-toma of ovary-a case report: a molecular and immunohisto-chemical analysis. Int J Gynecol Pathol 26:30-33, 2007.

90. Quirk JT, Natarajan N, Mettlin CJ: Age-specific ovarian cancer incidence rate patterns in the United States. Gynecol Oncol 99(1):248-250, 2005.

91. Williams SD: Malignant ovarian germ cell tumors. In Gershen-son DM, McGuire WP, Gore M, et al (eds): Gynecologic Cancer: Controversies in Management. Philadelphia: Churchill Livingstone, 2005, pp 499-502.

92. Berek JS, Hacker NF: Nonepithelial ovarian and fallopian tube cancers. In Berek JS, Hacker NF (eds): Practical Gynecologic Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005, pp 511-542.

93. Pectasides D, Pectasides E, Kassanos D: Germ cell tumors of the ovary. Cancer Treat Rev 34(5):427-441, 2008.

94. Gershenson DM: Management of ovarian germ cell tumors. J Clin Oncol 25(20):2938-2943, 2007.

95. Crum CP: The female genital tract. In Kumar V, Abbas AK, Fausto N (eds): Robbins and Cotran Pathologic Basis of Disease, 7th ed. Philadelphia: Elsevier, 2005.

96. Imai A, Furui T, Tamaya T: Gynecologic tumors and symptoms in childhood and adolescence: 10-years' experience. Int J Gyn-aecol Obstet 45(3):227-234,1994.

97. Leiserowitz GS, Xing G, Cress R, et al: Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 101(2):315-321, 2006.

98. Schwartz PE, Chambers SK, Chambers JT, et al: Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol 45(1):26-31,1992.

99. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers: International Germ Cell Cancer Collaborative Group. J Clin Oncol 15(2):594-603, 1997.

100. Malagon HD, Valdez AM, Moran CA, et al: Germ cell tumors with sarcomatous components: a clinicopathologic and immuno-histochemical study of 46 cases. Am J Surg Pathol 31(9):1356-1362, 2007.

101. Murugaesu N, Schmid P, Dancey G, et al: Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 24(30):4862-4866, 2006.

102. Kumar S, Shah JP, Bryant CS, et al: The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 110(2): 125-132, 2008.

103. Lai CH, Chang TC, Hsueh S, et al: Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 96(3):784-791, 2005.

104. O'Connor DM, Norris HJ: The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 13(4):283-289, 1994.

105. Marina N, London WB, Frazier AL, et al: Prognostic factors in children with extragonadal malignant germ cell tumors: a pedi-atric intergroup study. J Clin Oncol 24(16):2544-2548, 2006.

106. Peccatori F, Bonazzi C, Chiari S, et al: Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 86(3):367-372, 1995.

107. Slayton RE, Park RC, Silverberg SG, et al: Vincristine, dactino-mycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A gynecologic oncology group study (a final report). Cancer 56(2):243-248, 1985.

108. Williams S, Blessing JA, Liao SY, et al: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomy-cin: a trial of the gynecologic oncology group. J Clin Oncol 12(4):701-706, 1994.

109. Williams SD, Blessing JA, Moore DH, et al: Cisplatin, vinblas-tine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 111(1):22-27, 1989.

110. Williams SD, Blessing JA, Hatch KD, et al: Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 9(11):1950-1955, 1991.

111. Loehrer PJ S, Johnson D, Elson P, et al: Importance of bleomy-cin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13(2):470-476, 1995.

112. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a southeastern cancer study group protocol. J Clin Oncol 7(3):387-391, 1989.

113. Williams SD, Blessing JA, DiSaia PJ: Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience. Gynecol Oncol 52(3):287-291, 1994.

114. Bonazzi C, Peccatori F, Colombo N, et al: Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol 84(4):598-604, 1994.

115. Marina NM, Cushing B, Giller R, et al: Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a pediatric oncology group/children's cancer group intergroup study. J Clin Oncol 17(7):2137-2143, 1999.

116. Dark GG, Bower M, Newlands ES, et al: Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15(2):620-624, 1997.

117. Patterson DM, Murugaesu N, Holden L, et al: A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer 18(1):43-50, 2008.

118. Bafna UD, Umadevi K, Kumaran C, et al: Germ cell tumors of the ovary: Is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 11(4):300-304, 2001.

119. Billmire D, Vinocur C, Rescorla F, et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 39(3):424-429; discussion 424^29, 2004.

120. Einhorn LH, Brames MJ, Juliar B, et al: Phase II study of pacli-taxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 25(5):513-516, 2007.

121. Brewer M, Gershenson DM, Herzog CE, et al: Outcome and reproductive function after chemotherapy for ovarian dysgermi-noma. J Clin Oncol 17(9):2670-2675, 1999.

122. Low JJ, Perrin LC, Crandon AJ, et al: Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 15:89(2):391-398, 2000.

123. Tangir J, Zelterman D, Ma W, et al: Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 101(2):251-7, 2003.

124. de La Motte Rouge T, Pautier P, Duvillard P, et al: Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol 19(8):1435-1441, 2008.

125. Kang H, Kim TJ, Kim WY, et al: Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol Jul 23, 2008.

126. Schneider DT, Hilgenfeld E, Schwabe D, et al: Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 17(10):3226-3233, 1999.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment